# Stereotactic Radiotherapy for Oligoprogressive ER+/HER- Metastatic Breast Cancer, a Prospective Phase 2 Study (Oligopro-Breast)

> **NCT06925984** · NA · RECRUITING · sponsor: **Jules Bordet Institute** · enrollment: 48 (estimated)

## Conditions studied

- OligoProgressive Metastatic Disease

## Interventions

- **RADIATION:** SBRT

## Key facts

- **NCT ID:** NCT06925984
- **Lead sponsor:** Jules Bordet Institute
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-10-30
- **Primary completion:** 2028-05-01
- **Final completion:** 2030-05-01
- **Target enrollment:** 48 (ESTIMATED)
- **Last updated:** 2026-02-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06925984

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06925984, "Stereotactic Radiotherapy for Oligoprogressive ER+/HER- Metastatic Breast Cancer, a Prospective Phase 2 Study (Oligopro-Breast)". Retrieved via AI Analytics 2026-06-27 from https://api.ai-analytics.org/clinical/NCT06925984. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*